-
AC Immune Promising On Alzheimer's, But Light On Short-Term Catalysts, Says Credit Suisse
Friday, March 23, 2018 - 11:59am | 372Read More...While AC Immune SA (NASDAQ: ACIU)’s crenezumab Alzheimer's treatment could be a breakthrough if trials prove successful, the faraway approval and launch timelines for the drug could mean the stock will see few catalysts over the next 12 months, according to Credit Suisse. The Analyst...
-
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
Thursday, February 16, 2017 - 5:13pm | 1780Read More...Merck & Co, Inc. (NYSE: MRK) Tuesday reported it was halting its Phase 3 study of Alzheimer's treatment verubecestat in people with mild to moderate Alzheimer's disease (AD) after it was determined it had "virtually no chance of finding a positive clinical effect." In light...
-
AC Immune Out Positive On Crenezumab; What Does It Mean?
Monday, December 12, 2016 - 11:05am | 339Read More...Shares of AC Immune Ltd (NASDAQ: ACIU), a medical biotechnology company that focuses on the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases, soared higher by more than 23 percent after the company's partner Genentech published an editorial. AC Immune and Genentech have...
-
AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
Tuesday, October 18, 2016 - 11:15am | 464Read More...Credit Suisse initiated coverage of AC Immune Ltd (NASDAQ: ACIU) with an Outperform rating and an $18 price target. Alzheimer's Pure Play Analyst Alethia Young noted that the company's lead product crenezumab is in a late-stage trial in partnership with Roche Holding Ltd. (ADR) (OTC: RHHBY)....
